Sotera Health Company (SHC)

From the record

Sotera Health Company's filings since 2020 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Sotera Health Company's 7 filed years say what it did: revenue went from $778 million in fiscal 2019 to $1.2 billion in fiscal 2025, up 6.9% a year; it rose in 6 of 6 years; it never fell from a peak; net income was positive in 4 of 7 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Sotera Health Company's diluted share count grew about 0.7% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 18 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Sotera Health Company earned about 13 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 20 cents per dollar of everything the company owns. Leverage: it owed about 81 cents per dollar of assets, and net share issuance: its share count grew 0.5% over the year (the filed statements).

From the record

Sotera Health Company's standing among 10 graded names in its industry family: revenue of $1.2 billion in fiscal 2025 ranks in the top 39% by size; a net margin of 6.7% ranks in the top 15%; revenue growth of 5.1% a year over the last 3 filed years ranks in the bottom 35% (its annual reports).

From the record

Sotera Health Company's leadership, from its insiders' filings and its current reports: the chief executive on the record is Shader, Alton (Chief Executive Officer, as filed), filing under that title since 2026-05-27, 6 months (bottom 19% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 5.5 years (bottom 36%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (bottom 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Sotera Health Company's room to grow, from the newest filed statements (fiscal 2025): cash of $346 million against debt of $2.1 billion leaves -55% of its assets as net cash, bottom 5% of its family; cash from operations less capital spending is 12.8% of revenue (top 35%); a gross margin of 55.5% (top 44%) (its annual report).

From the record

Sotera Health Company's growth drivers, from the filed years to fiscal 2025: revenue grew 5.1% a year over the last three filed years against 6.9% over all 7, slowing (bottom 35% of its family); the newest year grew 5.7% (top 35%); capital spending grew -8.9% a year (bottom 35%) (its annual reports). Sotera Health Company reported 3 lines of business in fiscal 2025: Sterigenics at $756 million (65%), Nelson Labs at $220 million (19%), Nordion at $188 million (16%); 2 of 3 grew against the year before (its annual report).

From the record

Sotera Health Company's newest year against its own record: revenue of $1.2 billion in fiscal 2025 came in 1% above the $1.2 billion its prior three years' pace pointed to (top 25% of its family); net income of $78 million against a prior three-year average of $46 million (top 15%); a net margin of 6.7% against -4.8% before (top 35%) (its annual reports).